• uconn
  • uconn health
Page content relevant to:

Innovation Funding Opportunities

Below you will find a list of funding opportunities for research faculty and students in the areas of Agricultural Sciences, Life Sciences, Physical Sciences and opportunities for startups.  If you would like to have an opportunity added to the below list please contact: Taylor Renaud

COVID-19 Research Opportunities

Agricultural Sciences

Program

Deadline

Description

Corteva is Interested in Partnerships and Collaborations Rolling Admissions See website for proposal areas of interest.

Life Science

Program

Deadline

Description

Johnson & Johnson Nurses Innovate QuickFire Challenge on Mental Health January 15th, 2021 Johnson and Johnson invites nurses and nursing students worldwide to submit their nurse-led novel concepts, education programs, protocols[1], prevention or treatment approaches, screening tools, and consumer product ideas with the power to potentially transform mental health care and well-being for their fellow healthcare professionals or the patients they serve amid the current pandemic environment and beyond.
Novel Regenerative Approaches for Osteoarthritis January 18th, 2021 Client is interested in novel regenerative approaches for osteoarthritis
Targeting Cancer Cells with Aptamers January 18th, 2021 A global biotechnology company is currently interested in identifying nucleic acid-based aptamers that bind to targets specifically found on the surface of cancer cells.
Asahi Kasei Pharma Open Innovation Accepting applications:

January 7th-February 25th, 2021

Asahi Kasei Pharma would like to announce that we are publicly calling for new proposals related to drug development research as part its efforts for open innovation, to promote pharmaceutical research and development through enhanced cooperation with universities, research institutes, and enterprises around the world. More details. 
2021 Rheumatology Competitive Grant Program January 22, 2021 The intent of this Request for Proposal (RFP) is to support both clinical and basic science research on the pathogenesis and treatment of Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and/or Ankylosing Spondylarthrosis (AS) with a specific focus on projects that are most relevant to improving
patient care. All US investigators are encouraged to apply, including young investigators who are in the early stages of their career.
Next Generation Imaging Using Serial 18F-flutemetamol PET to Assess
Diagnostic Performance and/or Disease Stabilization in Patients with Transthyretin Amyloid cardiomyopathy (ATTR-CM) Treated with Tafamidis
Research Competitive Grant Program – Request for Proposals (RFP)
February 1, 2021 Through this Research RFP, Pfizer and GE Healthcare wish to support research projects focused on assessing both diagnostic performance and changes over time of 18F-flutemetamol cardiac uptake after initiation of Tafamidis treatment in subjects diagnosed with ATTR cardiac amyloidosis.
2021 Ulcerative Colitis Competitive Grant Program February 16th, 2021 The intent of this Request for Proposal (RFP) is to support both clinical and basic science research on the pathogenesis and treatment of Ulcerative Colitis (UC) with a specific focus on projects that are most relevant to improving patient care.
All US investigators are encouraged to apply, including young investigators who are in the early stages of their career. At least one award will be reserved for a young investigator
Inflammatory and Immune-Mediated
Dermatologic Disorders
Competitive Grant Program
February 24th, 2021 The intent of this Request for Proposal (RFP) is to support preclinical, clinical
and outcomes research through a competitive grant program with the intent
to increase medical knowledge in the diagnosis and management of
inflammatory and immune-mediated dermatologic disorders.
2021 Global Hemophilia ASPIRE March 1, 2021 Projects that will be considered for Pfizer support will focus on the following areas:
1. Basic and Clinical Science of Gene Therapy for Hemophilia,
2. Basic and Clinical Science of Tissue Factor Pathway Inhibitor (TFPI) and anti-TFPI monoclonal antibodies, 3. Burden of disease: Clinical Hemophilia A and B
Rare Treatment Accelerator (RTA) Rolling Admissions The Rare Treatment Accelerator programme connects academic groups, patient groups and early-stage biotechs with Healx to unlock the power of repurposed drugs for rare diseases. Working together, we can quickly turn your research, insights and promising repurposing assets into treatments that will benefit rare disease patients
Pfizer-Vaccines Areas of Interest Rolling Admissions Qualified researchers are invited to submit research proposals, according to the guidance and instructions found on www.pfizer.com/ISR. A proposal requesting Pfizer support (e.g., funding and/or drug supply) is not a guarantee of acceptance or approval of that proposal. Decisions on support for submissions are made by the applicable Pfizer Global Reviewers. 
Pfizer- Inflammation and Immunology Areas of Interest Rolling Admissions Qualified researchers are invited to submit research proposals, according to the guidance and instructions found on www.pfizer.com/ISR. A proposal requesting Pfizer support (e.g., funding and/or drug supply) is not a guarantee of acceptance or approval of that proposal. Decisions on support for submissions are made by the applicable Pfizer Global Reviewers. 
Pfizer- Rare Disease Areas of Interest Rolling Admissions Qualified researchers are invited to submit research proposals, according to the guidance and instructions found on www.pfizer.com/ISR. A proposal requesting Pfizer support (e.g., funding and/or drug supply) is not a guarantee of acceptance or approval of that proposal. Decisions on support for submissions are made by the applicable Pfizer Global Reviewers. 
Pfizer- Internal Medicine Areas of Interest Rolling Admissions Qualified researchers are invited to submit research proposals, according to the guidance and instructions found on www.pfizer.com/ISR. A proposal requesting Pfizer support (e.g., funding and/or drug supply) is not a guarantee of acceptance or approval of that proposal. Decisions on support for submissions are made by the applicable Pfizer Global Reviewers. 
Pfizer-Oncology Investigator Sponsored Research
Quarterly Application and Review Cycles
Quarterly Admissions More Details

 

Physical Sciences

Program Deadline Description
Next Generation Imaging Using Serial 18F-flutemetamol PET to Assess
Diagnostic Performance and/or Disease Stabilization in Patients with Transthyretin Amyloid cardiomyopathy (ATTR-CM) Treated with Tafamidis
Research Competitive Grant Program – Request for Proposals (RFP)
February 1, 2021 Through this Research RFP, Pfizer and GE Healthcare wish to support research projects focused on assessing both diagnostic performance and changes over time of 18F-flutemetamol cardiac uptake after initiation of Tafamidis treatment in subjects diagnosed with ATTR cardiac amyloidosis.
Corteva is Interested in Partnerships and Collaborations Rolling Admissions See website for proposal areas of interest.

Startup/Entrepreneurship

Program Deadline Description
CTNext Entrepreneur Innovation Awards (EIA)
February 2021 Online Pitch Competition
January 14th, 2021 The Entrepreneur Innovation Awards event features startup and early-stage companies vying for grants of $10,000 or more! There can be one, two, three or more winners – plus the Crowd Favorite and Judges’ Favorite grants of $2,000 each.
MassBio Partnering Week January 25th-29th, 2021 Are you a small biotech, an academic institution, or investigator looking for opportunities to collaborate with major biopharmaceutical organizations? Submit your application to request one-on-one partnering meetings with major biopharmaceutical and leading life sciences organizations in complementary focus areas.